Request Your Free Guide Now:

"Addressing market access challenges as CGTs expand to larger patient populations"

Cell and gene therapies (CGTs) represent a paradigm shift in the treatment of numerous complex diseases, offering potentially curative options that were once unimaginable. However, as these transformative therapies gain traction, CGT manufacturers face a multitude of market access challenges that must be addressed to realize the full potential of these therapies.

For your commercialization strategy to succeed, you should consider these approaches to improve market access:

• Increasing payer awareness to facilitate informed coverage decisions, especially where the CGTs are vying for attention and reimbursement alongside established treatments
• Innovating on pricing and reimbursement models as the market evolves to accommodate larger patient populations
• Transitioning treatment models to accommodate CGT administration in outpatient settings versus the more standard inpatient settings for CGTs that have already been approved

Central to overcoming these challenges is the need for comprehensive education and awareness efforts that engage all stakeholders, enabling a well-informed market capable of integrating CGTs into routine clinical practice. The following actionable recommendations to these multifaceted challenges are intended to help facilitate market access for CGTs in the U.S. healthcare system.

Download to learn more. 

Offered Free by: Cencora
See All Resources from: Cencora